[HTML][HTML] Antimyostatin treatment in health and disease: The story of great expectations and limited success
TL Nielsen, J Vissing, TO Krag - Cells, 2021 - mdpi.com
In the past 20 years, myostatin, a negative regulator of muscle mass, has attracted attention
as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical …
as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical …
Antimyostatin Treatment in Health and Disease: The Story of Great Expectations and Limited Success.
TL Nielsen, J Vissing, TO Krag - Cells, 2021 - europepmc.org
In the past 20 years, myostatin, a negative regulator of muscle mass, has attracted attention
as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical …
as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical …
Antimyostatin Treatment in Health and Disease: The Story of Great Expectations and Limited Success
TL Nielsen, J Vissing, TO Krag - 2021 - agris.fao.org
In the past 20 years, myostatin, a negative regulator of muscle mass, has attracted attention
as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical …
as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical …
Antimyostatin Treatment in Health and Disease: The Story of Great Expectations and Limited Success
TL Nielsen, J Vissing, TO Krag - Cells, 2021 - cir.nii.ac.jp
抄録< jats: p> In the past 20 years, myostatin, a negative regulator of muscle mass, has
attracted attention as a potential therapeutic target in muscular dystrophies and other …
attracted attention as a potential therapeutic target in muscular dystrophies and other …
Antimyostatin Treatment in Health and Disease: The Story of Great Expectations and Limited Success
TL Nielsen, J Vissing, TO Krag - Cells, 2021 - research.regionh.dk
In the past 20 years, myostatin, a negative regulator of muscle mass, has attracted attention
as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical …
as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical …
Antimyostatin Treatment in Health and Disease: The Story of Great Expectations and Limited Success.
TL Nielsen, J Vissing, TO Krag, C Fry - Cells (2073-4409), 2021 - search.ebscohost.com
In the past 20 years, myostatin, a negative regulator of muscle mass, has attracted attention
as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical …
as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical …
Antimyostatin Treatment in Health and Disease: The Story of Great Expectations and Limited Success
TL Nielsen, J Vissing, TO Krag - Cells, 2021 - pubmed.ncbi.nlm.nih.gov
In the past 20 years, myostatin, a negative regulator of muscle mass, has attracted attention
as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical …
as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical …
[HTML][HTML] Antimyostatin Treatment in Health and Disease: The Story of Great Expectations and Limited Success
TL Nielsen, J Vissing, TO Krag - Cells, 2021 - ncbi.nlm.nih.gov
In the past 20 years, myostatin, a negative regulator of muscle mass, has attracted attention
as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical …
as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical …